8-K

                                 UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                ________________
                                    FORM 8-K

                                 CURRENT REPORT

     Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934



Date of Report (Date of earliest event reported)    April 6, 2005
                                                    ----------------------------


                          GENELABS TECHNOLOGIES, INC.
- --------------------------------------------------------------------------------
             (Exact name of registrant as specified in its charter)

        California                       0-19222               94-3010150
- -------------------------------------------------------------------------------
(State or other jurisdiction     (Commission File Number)     (IRS Employer
    of incorporation)                                       Identification No.)

    505 Penobscot Drive, Redwood City, California                94063
- --------------------------------------------------------------------------------
     (Address of principal executive offices)                 (Zip Code)

Registrant's telephone number, including area code   (650) 369-9500
                                                   -----------------------------


- -------------------------------------------------------------------------------
         (Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligations of the registrant under any of
the following provisions (see General Instruction A.2. below):

[ ]  Written communications pursuant to Rule 425 under the Securities Act
     (17 CFR 230.425)
[ ]  Soliciting material pursuant to Rule 14a-12 under the Exchange Act
     (17 CFR 240.14a-12)
[ ]  Pre-commencement communications pursuant to Rule 14d-2(b) under the
     Exchange Act (17 CFR 240.14d-2(b))
[ ]  Pre-commencement communications pursuant to Rule 13e-4(c) under the
     Exchange Act (17 CFR 240.13e-4(c))




Item 8.01         OTHER EVENTS.

         On April 6, 2005 Genelabs Technologies, Inc. (the "Company") issued a
press release announcing the results of a preliminary analysis of a Phase III
clinical trial conducted by its licensee, Genovate Biotechnology Co., Ltd.,
which did not demonstrate a statistically significant benefit among the
patients receiving prasterone compared to the patients taking placebo. The
clinical trial, which was not conducted under a U.S. Investigational New Drug
Application (IND), was a randomized, placebo-controlled, double-blind study
conducted at six medical centers in Taiwan to determine the effect of
prasterone on the bone mineral density of women with systemic lupus
erythematosus (SLE or lupus) receiving glucocorticoids. The Company stated that
when the analysis of this study is complete, it plans to meet with the U.S.
Food and Drug Administration (FDA) to determine its next steps. A copy of the
press release announcing the results is attached as Exhibit 99.1 hereto.

Item 9.01         FINANCIAL STATEMENTS AND EXHIBITS.

(c) Exhibits.

99.1     Press Release of Registrant, dated April 6, 2005, entitled "Genelabs
         Announces Preliminary Results of Genovate's Clinical Trial GBL03-00 in
         Women with Systemic Lupus Erythematosus."







                                   SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned, thereto duly authorized.


                                              GENELABS TECHNOLOGIES, INC.



                                              By:  /s/  Matthew M. Loar
                                                  -----------------------------
                                              Name:   Matthew M. Loar
                                              Title:  Chief Financial Officer
Date:  April 7, 2005

EX-99

                                                                   Exhibit 99.1


Contact:     Matthew M. Loar
             Chief Financial Officer
             Phone: 650-562-1424

FOR IMMEDIATE RELEASE:
- ----------------------


                     GENELABS ANNOUNCES PRELIMINARY RESULTS
                     OF GENOVATE'S CLINICAL TRIAL GBL03-00
                   IN WOMEN WITH SYSTEMIC LUPUS ERYTHEMATOSUS

REDWOOD CITY, Calif. - April 6, 2005 - Genelabs Technologies, Inc.
(Nasdaq:GNLB) announced today results of a preliminary analysis of a Phase III
clinical trial conducted by its licensee, Genovate Biotechnology Co., Ltd.,
which did not demonstrate a statistically significant benefit among the
patients receiving prasterone compared to the patients taking placebo. The
clinical trial, which was not conducted under a U.S. Investigational New Drug
Application (IND), was a randomized, placebo-controlled, double-blind study
conducted at six medical centers in Taiwan to determine the effect of
prasterone on the bone mineral density of women with systemic lupus
erythematosus (SLE or lupus) receiving glucocorticoids. The primary endpoint
was bone mineral density at the lumbar spine and the treatment duration was
nine months.

"Development of a new drug for lupus, a complex and debilitating disease, has
proven to be very challenging," stated James A.D. Smith, President and Chief
Executive Officer. "When the analysis of this study is complete we plan to meet
with the FDA and determine our course of action for Prestara(TM), our
formulation of prasterone."

"While we are disappointed by these preliminary results, over the last few
years we have also devoted significant resources to discovery of new drugs for
treatment of hepatitis C infection, and I am very enthusiastic about our HCV
pipeline," continued Mr. Smith. "One of our HCV programs is being conducted in
collaboration with Gilead Sciences, under which Genelabs is leading the
research efforts, applying nucleoside compounds to the inhibition of HCV.
Independent of the Gilead collaboration, another of our HCV discovery programs,
to which we retain all rights, has advanced into preclinical development."

About Genelabs Technologies
- ---------------------------
Genelabs Technologies, Inc. is a biopharmaceutical company focused on the
discovery and development of pharmaceutical products to improve human health.
We have built drug discovery and clinical development capabilities that can
support various research and development projects. Genelabs is currently
concentrating its capabilities on developing a late-stage product for lupus,
discovering novel compounds that selectively inhibit replication of the
hepatitis C virus and advancing preclinical development of compounds from this
hepatitis C virus drug discovery program. We believe that these high-risk,
potentially high reward programs focus our research and development expertise
in areas where we have the opportunity to generate either first-in-class or
best-in-class products that will address diseases for which current therapies
are inadequate. For more information, please visit www.genelabs.com.

Note: Genelabs(R) and the Genelabs logo are registered trademarks and
Prestara(TM) is a trademark of Genelabs Technologies, Inc.

NOTE ON FORWARD LOOKING STATEMENTS AND RISKS: This press release contains
forward-looking statements including statements regarding the data from
Genovate's clinical trial (which are preliminary and subject to change),
Genelabs' plans to submit the clinical results to the FDA, and possible actions
of the FDA. Forward-looking statements also include statements regarding the
progress of the Company's hepatitis C virus research programs. These
forward-looking statements are based on Genelabs' current expectations and are
subject to uncertainties and risks that could cause actual results to differ
materially from the statements made. Uncertainties and risks include, without
limitation, errors, omissions or adverse events in the recently completed
Prestara(TM) and Genovate clinical trials and ongoing clinical trials; whether
the results of Genelabs' or Genovate's clinical trials and other supporting
information will be sufficient to support the approval of Prestara(TM) by the
FDA, the European Agency for Evaluation of Medicinal Products and other
regulatory authorities; delays regarding the regulatory approval process
including the timing and scope of approval received, if any; failures or
setbacks in our collaboration with Gilead or in our HCV research programs;
unexpected expenses and Genelabs' capital requirements and history of operating
losses. There can be no assurance that Genelabs will continue development of
Prestara(TM). The company currently does not have regulatory applications
submitted for review of Prestara(TM) outside the U.S. In addition, neither U.S.
nor other regulatory authorities have made a determination as to the safety or
efficacy of Prestara(TM) for SLE. Please see the information appearing in the
Genelabs' filings with the Securities and Exchange Commission, including our
most recent Annual Report on Form 10-K, under the captions "Risk Factors" and
"Forward-Looking Statements" for more discussion regarding these uncertainties
and risks and others associated with the company's research programs, early
stage of development and other risks which may affect the company or cause
actual results to differ from those included in the forward-looking statements.
Genelabs does not undertake any obligation to update these forward-looking
statements or risks to reflect events or circumstances after the date of this
release.